Bottom line
GGHCX vs RYHIX: the short answer
GGHCX (INVESCO Health Care Fund) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 52% by weight.
GGHCX is cheaper at 1.07% vs 1.38% — a difference of $31 a year per $10,000 invested.
Over five years, RYHIX returned +5.1% a year vs +2.6% for GGHCX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
GGHCX vs RYHIX side by side
| GGHCX | RYHIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Invesco | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.07% | 1.38% |
| Annual cost per $10k | $107 | $138 |
| 10-yr cost on $10k (prospectus) | $1,784 | $1,709 |
| Max front load | 5.5% | — |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +9.2% | +14.4% |
| 5-yr return (annualized) | +2.6% | +5.1% |
| 10-yr return (annualized) | +5.8% | +7.9% |
| Best quarter | +19.6% | +18.7% |
| Worst quarter | −16.5% | −14.4% |
| Net assets (fund) | $1.2B | $19.4M |
| Number of holdings | 82 | 135 |
| Portfolio turnover | 59% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GGHCX | RYHIX | Difference |
|---|---|---|---|
| 2025 | +15.5% | +14.4% | +1.1% |
| 2024 | +4.0% | +0.6% | +3.4% |
| 2023 | +3.1% | +5.8% | −2.8% |
| 2022 | −13.5% | −11.6% | −1.9% |
| 2021 | +12.2% | +19.2% | −7.0% |
| 2020 | +14.5% | +18.9% | −4.5% |
| 2019 | +32.0% | +22.8% | +9.2% |
| 2018 | +0.5% | +1.6% | −1.1% |
| 2017 | +15.5% | +23.5% | −8.0% |
| 2016 | −11.7% | −9.4% | −2.3% |
Source: Fund prospectus bar charts
Holdings overlap
11 of GGHCX's top 25 holdings also appear in RYHIX's top 25.
| Holding | GGHCX | RYHIX |
|---|---|---|
| Eli Lilly and Co. | 10.59% | 3.63% |
| Johnson & Johnson | 6.76% | 2.88% |
| UnitedHealth Group Inc. | 6.17% | 2.22% |
| Merck & Co., Inc. | 4.59% | 2.04% |
| AbbVie Inc. | 4.03% | 2.52% |
| Gilead Sciences, Inc. | 3.63% | 1.39% |
| CVS Health Corp. | 2.52% | 1.31% |
| Cardinal Health, Inc. | 2.10% | 0.86% |
| Vertex Pharmaceuticals Inc. | 2.01% | 1.34% |
| Edwards Lifesciences Corp. | 1.56% | 0.84% |
| Thermo Fisher Scientific Inc. | 1.55% | 1.61% |
Source: SEC Form N-PORT
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between GGHCX and RYHIX?
Which is cheaper, GGHCX or RYHIX?
Should I own both GGHCX and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.